Mylan launches Generic Robaxin injection
This product is the generic version of Hikma Maple Ltd.’s Robaxin®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.
The findings were presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held December 7-11 in Phoenix, Arizona. Dasotraline, a new chemical entity discovered
The Manocept platform serves as the molecular backbone of Navidea’s FDA-approved, activated macrophage-targeting agent, Lymphoseek (technetium Tc 99m tilmanocept) injection. Preclinical data being developed by the Company using